Acrivon Therapeutics to Participate in Two Investor Conferences in September
August 30 2023 - 8:00AM
Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”)
(Nasdaq: ACRV), a clinical stage biopharmaceutical company
developing precision oncology medicines that it matches to patients
whose tumors are predicted to be sensitive to each specific
medicine by utilizing its proprietary proteomics-based patient
responder identification platform, today announced the company’s
management team will participate in two investor conferences in
September.
- Citi’s 18th
Annual BioPharma Conference in Boston, MA
- Company
management will be hosting meetings on Wednesday, September 6,
2023
- 2023 Wells
Fargo Healthcare Conference in Boston, MA
- Acrivon’s chief
executive officer and president, Peter Blume-Jensen, M.D., Ph.D.,
will present on Thursday, September 7, 2023 at 3:45 p.m. ET
To access the live webcast of the Wells Fargo
presentation, visit the Events & Presentations page within the
investor section of the company’s website at
https://ir.acrivon.com/news-events/events-presentations. A replay
of the webcast will be available via the same link for 90 days
following the event.
About Acrivon Therapeutics Acrivon is a
clinical stage biopharmaceutical company developing precision
oncology medicines that it matches to patients whose tumors are
predicted to be sensitive to each specific medicine by utilizing
Acrivon’s proprietary proteomics-based patient responder
identification platform, Acrivon Predictive Precision Proteomics,
or AP3. The AP3 platform enables the creation of drug-specific
proprietary OncoSignature companion diagnostics that are used to
identify the patients most likely to benefit from Acrivon’s drug
candidates. Acrivon is currently advancing its lead candidate,
ACR-368, a selective small molecule inhibitor targeting CHK1 and
CHK2 in a potentially registrational Phase 2 trial across multiple
tumor types. Acrivon’s ACR-368 OncoSignature test, which has not
yet obtained regulatory approval, has been extensively evaluated in
preclinical studies, including in two separate, blinded,
prospectively-designed studies on pretreatment tumor biopsies
collected from past third party Phase 2 trials in patients with
ovarian cancer treated with ACR-368. In addition to ACR-368,
Acrivon is also leveraging its proprietary AP3 precision medicine
platform for developing its internally-discovered preclinical stage
pipeline programs targeting two critical nodes in the DNA Damage
Response, or DDR, including WEE1, a protein serine/threonine
kinase, and the closely related PKMYT1.
Forward-Looking Statements This press release
includes certain disclosures that contain “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 about us and our industry that involve
substantial risks and uncertainties. All statements other than
statements of historical facts contained in this press release,
including statements regarding our future results of operations or
financial condition, business strategy and plans and objectives of
management for future operations, are forward-looking statements.
In some cases, you can identify forward-looking statements because
they contain words such as “anticipate,” “believe,” “contemplate,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or the negative of these words or other similar terms or
expressions. Forward-looking statements are based on Acrivon’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Factors that
could cause actual results to differ include, but are not limited
to, risks and uncertainties that are described more fully in the
section titled “Risk Factors” in our reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this press release are made as of this date, and
Acrivon undertakes no duty to update such information except as
required under applicable law.
Investor and Media Contacts: Adam
Levyalevy@acrivon.com
Alexandra Santos asantos@wheelhouselsa.com
Acrivon Therapeutics (NASDAQ:ACRV)
Historical Stock Chart
From Apr 2024 to May 2024
Acrivon Therapeutics (NASDAQ:ACRV)
Historical Stock Chart
From May 2023 to May 2024